U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 13

1.

Gene expression of disseminated neuroblastoma

(Submitter supplied) Comprehensive expression profiling of disseminated neuroblastoma with favorable and unfavorable outcome using SAGE. Results provide insight into the molecular pathogenesis of spontaneous regression and progression of metastatic neuroblastoma and may be used for improving risk estimation of patients with disseminated neuroblastoma. Keywords: gene expression SAGE-based, neuroblastoma, primary tumor, disseminated disease
Organism:
Homo sapiens
Type:
Expression profiling by SAGE
Platform:
GPL4
9 Samples
Download data
Series
Accession:
GSE4991
ID:
200004991
2.

Prediction of Recurrence-Free Survival in Postoperative NSCLC Patients—a Useful Prospective Clinical Practice

(Submitter supplied) Background: One of the main fields of lung cancer research is identifying patients who are at high risk of post-resection recurrence. Individual recurrence risk evaluation by accurate but simple and reproducible method is needed for the clinical practice. Results: The log-rank test and further selection by our criteria of assayability generated 87 genes from microarray data with significant level 5%. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
138 Samples
Download data
Series
Accession:
GSE8894
ID:
200008894
3.

Classification of neuroblastoma by integrating gene expression pattern with regional alterations in DNA copy number

(Submitter supplied) The specific genes that influence neuroblastoma biology and are targeted by genomic alterations remain largely unknown. We quantified mRNA expression in a highly annotated series of 101 prospectively collected diagnostic neuroblastoma primary tumors and the expression profiles were determined using Affymetrix U95Av2 arrays. Comparisons between the sample groups allow the identification of genes with localized expression patterns. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL8300
102 Samples
Download data: CEL
Series
Accession:
GSE3960
ID:
200003960
4.

Two distinct gene signatures identify malignant Neuroblast and Schwannian stromal cells of Neuroblastic Tumors

(Submitter supplied) Tumor tissue heterogeneity is a well known feature of several solid tumors. Neuroblastic Tumors (NTs) is a group of paediatric cancers with a great tissue heterogeneity. Most of NTs are composed of undifferentiated, poorly differentiated or differentiating neuroblastic (Nb) cells with very few or absent Schwannian stromal (SS) cells: these tumors are grouped as Neuroblastoma (Schwannian stroma-poor). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL96
28 Samples
Download data: CEL
Series
Accession:
GSE7529
ID:
200007529
5.

Gene expression signatures predict outcome in non-muscle invasive bladder carcinoma - a multi-center validation study

(Submitter supplied) Background Clinically useful molecular markers predicting the clinical course of patients diagnosed with non-muscle invasive bladder cancer are needed to improve treatment outcome. Methods We used custom designed oligonucleotide microarrays to validate four previously reported gene expression signatures for molecular diagnosis of disease stage and carcinoma in situ, and for predicting disease recurrence and progression. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL4060
808 Samples
Download data: TXT
Series
Accession:
GSE5479
ID:
200005479
6.

An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma

(Submitter supplied) The prognosis of children with metastatic stage 4 neuroblastoma (NB) has remained poor in the past decade. Using microarray analyses of 342 primary tumors, we here developed and validated an easy to use gene expression-based risk score including 18 genes, which can robustly predict the outcome of stage 4 patients. This classifier was a significant predictor of overall survival in two independent validation cohorts (cohort 1 (n=214): P=6.3x10-5; cohort 2 (n=27): P=3.1x10-2). more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL16876
27 Samples
Download data: TXT
Series
Accession:
GSE79910
ID:
200079910
7.

miRNA expression profiling in high-risk neuroblastoma

(Submitter supplied) In the present study we evaluated the miRNA expression profile of 31 high risk, stage 4 neuroblastoma patients.
Organism:
Homo sapiens
Type:
Non-coding RNA profiling by array
Platform:
GPL8227
31 Samples
Download data: TXT
Series
Accession:
GSE16444
ID:
200016444
8.

Oligonucleotide array CGH in high-risk neuroblastoma tumors

(Submitter supplied) We performed array CGH in high-risk neuroblastoma tumors in order to compare genome aberrations with expression of small non-coding RNAs.
Organism:
Homo sapiens
Type:
Genome variation profiling by array
Platforms:
GPL2873 GPL5477
33 Samples
Download data: TXT
Series
Accession:
GSE14109
ID:
200014109
9.

Primary human neuroblastoma

(Submitter supplied) Reference1: Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata T, Kubo H, Goto T, Yamada S, Yoshida Y, Fuchioka M, Ishii S, Nakagawara A. Expression profiling of human primary Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell. 2005 Apr;7(4):337-50. To predict the prognosis of neuroblastoma patients and choose a better therapeutic protocol, we developed a cDNA microarray carrying 5340 genes obtained from primary neuroblastomas and examined 136 tumor samples. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platforms:
GPL1874 GPL1875
186 Samples
Download data
Series
Accession:
GSE2283
ID:
200002283
10.

Mefloquine treatment of NG108 rat neuronal cells

(Submitter supplied) This data series describes expression data for eight paired, control and treated cell cultures obtained on independent occasions. NG108 rat neuronal cell cultures were exposed to either 0.25% DMSO (control) or 4400 ng/ml mefloquine (treated) for two hours. Validation: Modulation of the following transcripts by mefloquine was confirmed by semi-quantitative RT-PCR: U30186, X63594cds_g_at, X63594cds_at, X17163cds_s_at, rc_AI175959 and rc_AA945867 (unpaired, unequal variance, one tailed t-test, p < 0.05). more...
Organism:
Rattus norvegicus
Type:
Expression profiling by array
Dataset:
GDS199
Platform:
GPL89
16 Samples
Download data
Series
Accession:
GSE39
ID:
200000039
11.
Full record GDS199

Mefloquine treatment of NG108 neuroblastoma cells

Neuroblastoma cells NG108 exposed to a physiological dose (4400 ng/ml) of antimalarial mefloquine (Lariam), or 0.25% DMSO (control), for 2 hours. Mefloquine appears to disrupt neuronal function through disrupted calcium homeostasis and ER stress.
Organism:
Rattus norvegicus
Type:
Expression profiling by array, count, 2 agent sets
Platform:
GPL89
Series:
GSE39
16 Samples
Download data
12.

Identification Of Neuroblastoma Metastasis Associated Genes

(Submitter supplied) Metastatic relapse is the major cause of death in neuroblastoma (NB), yet there are no therapies to specifically target metastases. To understand the molecular mechanisms mediating NB metastasis, we developed a mouse model using intracardiac injection and in vivo selection to isolate metastatic subpopulations that exhibited a higher propensity for bone and central nervous system metastases. Gene expression profiling revealed two distinct subtypes, primary and metastatic, with differential regulation of 412 genes and multiple pathways including CADM1, SPHK1, and YAP/TAZ whose expression independently predicted survival. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
16 Samples
Download data: CEL
Series
Accession:
GSE90121
ID:
200090121
13.

Predicting Neuroblastoma Using Developmental Signals and a Logic-Based Model

(Submitter supplied) Genomic information from human patient samples of pediatric neuroblastoma cancers and known outcomes have led to specific gene lists put forward as high risk for disease progression. However, the reliance on gene expression correlations rather than mechanistic insight has shown limited potential and suggests a critical need for molecular network models that better predict neuroblastoma progression. In this study, we construct and simulate a molecular network of developmental genes and downstream signals in a 6-gene input logic model that predicts a favorable/unfavorable outcome based on the outcome of the four cell states including cell differentiation, proliferation, apoptosis, and angiogenesis. We simulate the mis-expression of the tyrosine receptor kinases, trkA and trkB, two prognostic indicators of neuroblastoma, and find differences in the number and probability distribution of steady state outcomes. We validate the mechanistic model assumptions using RNAseq of the SHSY5Y human neuroblastoma cell line to define the input states and confirm the predicted outcome with antibody staining. Lastly, we apply input gene signatures from 77 published human patient samples and show that our model makes more accurate disease outcome predictions for early stage disease than any current neuroblastoma gene list. These findings highlight the predictive strength of a logic-based model based on developmental genes and offer a better understanding of the molecular network interactions during neuroblastoma disease progression.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL16791
3 Samples
Download data: TXT
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=3|qty=3|blobid=MCID_668e5182097f457047015a47|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center